+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Restless Legs Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517507
  • Report
  • 63 pages
  • Prescient & Strategic Intelligence Private Limited
1 of 2
Restless Leg Syndrome Therapeutics Pipeline in 2018

The study analyzed that the restless leg syndrome therapeutics pipeline comprises of eight drug candidates in different stages of development.

Insights on Pipeline Segments

Around 62% of the pipeline drug candidates are being developed as small molecule for the treatment of RLS. Hisamitsu Pharmaceutical Co., Inc. is in a process to conduct Phase III clinical trial on its developmental drug for the treatment of RLS. In September 2017, AXIM Biotechnologies Inc. announced that it was conducting Phase I and a proof of concept clinical trial (Phase II) of MedChew RL for treatment of RLS in Israel.

Technological Advancements Driving the Growth of RLS Therapeutics Pipeline

Various new technologies are being used by the companies for the development of drugs to treat RLS. For instance, Hisamitsu Pharmaceutical Co., Inc. is using Hisamitsu’s TDDS technology to deliver its developmental product ropinirole hydrochloride into the body through skin to maintain an adequate concentration in the blood for a long time and to avoid the first-pass effect in the liver. Alexza Pharmaceuticals Inc. is using its propriety staccato technology for the delivery of its development drug through inhalation.

Positive Clinical Trial Results Spur the Growth of RLS Therapeutics Pipeline

The drugs candidates that are being developed by the different pharmaceutical companies have demonstrated positive clinical trial results which in-turn increase their further development. For instance, In April 2017, Merz Pharma GmbH & Co KgaA announced that incobotulinumtoxin demonstrated significant improvement of RLS score in the treatment of subjects with restless leg syndrome.

Rise in Patent Approvals for RLS Therapeutics Expected to Provide Collaborative Opportunities to the Pharmaceutical Companies

It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of RLS. In April 2017, Omeros Corporation announced that it owned two issued patents and one pending patent application in the U.S., and 21 issued patents and 12 pending patent applications in foreign markets directed to its discoveries linking PDE7 Program - OMS527 to movement disorders. Patent approval help in increasing opportunities for invention improvement and uniqueness.

Some of the key players developing drugs for the treatment of restless leg syndrome include Hisamitsu Pharmaceutical Co., Inc., Merz Pharma GmbH & Co KgaA, AXIM Biotechnologies Inc., and Alexza Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
2 of 2
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by industry participant by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.2 Sign & Symptoms
4.3 Epidemiology
4.4 Causes
4.5 Diagnosis
4.6 Prevention and Treatment
4.7 Key Drivers
4.7.1 Driver 1
4.7.2 Driver 2
4.8 Key Barriers
4.8.1 Barrier 1
4.9 RLS Therapeutics Pipeline Analysis
4.9.1 Pipeline Analysis by Phase
4.9.2 Pipeline Analysis by Molecule Type
4.9.3 Pipeline Analysis by Route of Administration
4.9.4 Pipeline Analysis by Company

5. RLS Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase III
5.1.1 NLS-2
5.2 Phase II
5.2.1 BP1.4979 Clinical trials
5.2.2 Xx Clinical trials Clinical trials results
5.2.3 Xx Clinical trials Strategic development Technology
5.2.4 Xx Clinical trials Strategic development
5.2.5 Xx Clinical trials Technology
5.3 Pre-Clinical
5.3.1 OMS527 Strategic development
5.3.2 Xx Clinical trials Technology

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Player Benchmarking for RLS Therapeutics Pipeline
7.2 SWOT Analysis of RLS Therapeutics Pipeline

8. Company Profiles
8.1 NLS Pharma Group
8.1.1 Business Overview
8.1.2 Product Offerings
8.2 Xx
8.2.1 Business Overview
8.2.2 Product Offerings
8.3 Xx
8.3.1 Business Overview
8.3.2 Product Offerings
8.4 Xx
8.4.1 Business Overview
8.4.2 Product Offerings
8.5 Xx
8.5.1 Business Overview
8.5.2 Product Offerings
8.6 Xx
8.6.1 Business Overview
8.6.2 Product Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 Pipeline Analysis of Rls Therapeutics, by Company (2018)
Table 2 Description of Nls-2
Table 3 Description of Xx
Table 4 Description of Xx
Table 5 Clinical Trials of Xx
Table 6 Description of Xx
Table 7 Description of Xx
Table 8 Description of Xx
Table 9 Clinical Trials of Xx
Table 10 Description of Oms527
Table 11 Description of Xx
Table 12 Nls Pharma Group - At a Glance
Table 13 Xx - At a Glance
Table 14 Xx - At a Glance
Table 15 Xx - At a Glance
Table 16 Xx - At a Glance
Table 17 Xx - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: Rls Drug Candidates In Development (2018)
Fig 5: Rls Pipeline Split, by Molecule Type (2018)
Fig 6: Rls Pipeline Split, by Route of Administration (2018)
Fig 7: Breakdown of Clinical Trials, by Region
Fig 8: Breakdown of Clinical Trials, by Trial Status
Fig 9: Key Player Benchmarking
Fig 10: SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2